VCRE — Vicore Pharma Holding AB
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2124403 ·
Sweden
Last close
$9.00
Market Cap
$253.48M
52W High
$17.80
52W Low
$7.88
ADV30
28,242
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,213,000 | 2,213,000 | -150,104,000 | -142,844,000 | 929,871,000 | 428,589,000 | 76,245,000 |
| Mar 2026 | 602,000 | 602,000 | -123,845,000 | -108,616,000 | 1,077,265,000 | 377,423,000 | 86,354,000 |
| Dec 2025 | 419,000 | 419,000 | -133,707,000 | -137,103,000 | 1,218,637,000 | 578,147,000 | 123,175,000 |
| Sep 2025 | — | — | — | — | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-262,368,000
Investing CF
$-45,137,000
Financing CF
$15,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-19.20
As of
2026-10-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,920,916,000
Inventory
—
Receivables
$20,459,000
ST Investments
$477,054,000
EBIT TTM
$-479,976,000
Pretax Income TTM
$-503,667,000
Interest Exp TTM
$23,691,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,817,000 | -454,445,000 | -477,474,000 | 1,218,637,000 | 123,175,000 | 1,095,462,000 | -375,737,000 |
| Dec 2024 | 109,346,000 | -190,360,000 | -168,634,000 | 1,195,574,000 | 66,245,000 | 1,129,329,000 | -164,946,000 |
| Dec 2023 | 0 | -320,889,000 | -310,942,000 | 497,838,000 | 42,449,000 | 455,389,000 | -249,583,000 |
| Dec 2022 | 0 | -287,494,000 | -288,422,000 | 338,007,000 | 48,924,000 | 289,083,000 | -299,919,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | $253.14M | $3.89 | — |
| AMRN | AMARIN CORP PLC\UK | $254.11M | $12.03 | — |
| IMRX | Immuneering Corp | $254.91M | $3.94 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $249.93M | $2.64 | — |
| UPB | Upstream Bio, Inc. | $257.42M | $4.70 | — |
News headlines (Yahoo Finance, 1h cache)
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-17 06:20 · Yahoo
Vicore Pharma to Participate in Upcoming Healthcare Conferences
2026-09-01 06:20 · Yahoo
Increase in Number of Shares and Votes in Vicore Pharma
2026-09-30 07:20 · Yahoo
Vicore Pharma to Participate in the Leerink Therapeutics Forum
2026-07-07 06:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.